Jennifer Losavio Steinbeck, M.D. Internal Medicine - Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 880 W Central Rd, Suite 8100, Arlington Heights, IL 60005 Phone: 847-255-5030 |
Dr. Luis F Guzman Vinasco, MD Internal Medicine - Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 880 W. Central Road, Suite 8100, Arlington Heights, IL 60005 Phone: 847-255-5030 Fax: 847-255-0156 |
Dr. Vern H Kerchberger Jr., MD Internal Medicine - Infectious Disease Medicare: Not Enrolled in Medicare Practice Location: 880 W. Central Rd., Suite 8100, Arlington Heights, IL 60005 Phone: 847-255-5030 Fax: 847-255-0156 |
Dr. Guy T Kochvar, MD Internal Medicine - Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 880 W. Central Rd., Suite 8100, Arlington Heights, IL 60005 Phone: 847-255-5030 Fax: 847-255-0156 |
Trevor J Slom, MD Internal Medicine - Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 880 W. Central Rd., Suite 8100, Arlington Heights, IL 60005 Phone: 847-255-5030 Fax: 847-255-0156 |
News Archive
Almost half of UK women could be suffering from a lack of vitamin A due to a previously undiscovered genetic variation, scientists at Newcastle University have found.
IsoRay, Inc. announced, today, it has completed an initial feasibility study, which demonstrates the ability to use its patented Cesium-131 (Cs-131) brachytherapy seeds (internal radiation therapy) in accelerated partial breast irradiation (APBI) for breast cancer treatment.
Liver cirrhosis is a worldwide disease with an incidence of 5 - 10% and represents a major health problem everywhere. Prognosis depends on the degree of liver damage and etiology of cirrhosis.
A cancer survivor is defined as anyone who has been diagnosed with cancer, from the time of diagnosis through the balance of his or her life. The findings are published in the June 25 issue of CDC's Morbidity and Mortality Weekly Report, "Cancer Survivorship - United States, 1971 - 2001."
A monoclonal antibody targeting a well known cell surface protein inhibited prostate cancer growth and metastasis in an aggressive form of the disease that did not respond to hormone therapy, according to a study by researchers with the UCLA Department of Urology and UCLA's Jonsson Comprehensive Cancer Center.
› Verified 3 days ago